Jade Biosciences (JBIO)
NASDAQ:JBIO
JBIO Stock Chart & Stats
$15.49
--
Market closed
$15.49
--
Day’s Range― - ―
52-Week Range$6.57 - $100.10
Previous CloseN/A
VolumeN/A
Average Volume (3M)127.19K
Market Cap
$763.91M
Enterprise Value$417.66M
Total Cash (Recent Filing)$336.16M
Total Debt (Recent Filing)$724.00K
Price to Earnings (P/E)―
Beta>-0.01
Next Earnings
May 18, 2026EPS Estimate
-0.48Next Dividend Ex-DateN/A
Dividend Yield14.68%
Share Statistics
EPS (TTM)-0.45
Shares Outstanding49,316,288
10 Day Avg. Volume252,880
30 Day Avg. Volume127,195
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.46
Price to Sales (P/S)0.00
P/FCF Ratio-5.10
Enterprise Value/Market Cap0.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-18.98K
Enterprise Value/Ebitda-4.53
Forecast
1Y Price Target
$29.70Price Target Upside91.74% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.08
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical ProgressPhase I biomarker and safety readouts for JADE101 could validate target engagement and inform dosing, reducing program risk and supporting progression to patient trials.
Differentiation And ImmunogenicityJADE101's fully human design and novel epitope targeting aim to lower anti-drug antibody risk seen with earlier APRIL therapies, which may preserve exposure and improve effectiveness.
Market OpportunityRising diagnoses and limits of existing treatments create demand for safer, more effective options, positioning JADE101 to capture meaningful market share if clinical benefits are confirmed.
Bears Say
Competitive LandscapeMultiple late-stage APRIL and APRIL/BAFF candidates and large pharma B-cell modulator programs intensify competition, which could limit pricing power and addressable market for new entrants.
Financial PositionReporting no revenue and a net loss above expectations highlights ongoing cash burn and raises the likelihood of future financing that could dilute shareholders or constrain development.
Program DelaysA delay in the JADE301 program increases execution risk and could slow the timeline for additional clinical milestones that would drive valuation.
Jade Biosciences News
JBIO FAQ
What was Jade Biosciences’s price range in the past 12 months?
Jade Biosciences lowest stock price was $6.57 and its highest was $100.10 in the past 12 months.
What is Jade Biosciences’s market cap?
Jade Biosciences’s market cap is $763.91M.
When is Jade Biosciences’s upcoming earnings report date?
Jade Biosciences’s upcoming earnings report date is May 18, 2026 which is in 44 days.
How were Jade Biosciences’s earnings last quarter?
Jade Biosciences released its earnings results on Mar 06, 2026. The company reported -$0.451 earnings per share for the quarter, beating the consensus estimate of -$0.482 by $0.031.
Is Jade Biosciences overvalued?
According to Wall Street analysts Jade Biosciences’s price is currently Undervalued.
Does Jade Biosciences pay dividends?
Jade Biosciences pays a Notavailable dividend of $2.4 which represents an annual dividend yield of 14.68%. See more information on Jade Biosciences dividends here
What is Jade Biosciences’s EPS estimate?
Jade Biosciences’s EPS estimate is -0.48.
How many shares outstanding does Jade Biosciences have?
Jade Biosciences has 49,316,288 shares outstanding.
What happened to Jade Biosciences’s price movement after its last earnings report?
Jade Biosciences reported an EPS of -$0.451 in its last earnings report, beating expectations of -$0.482. Following the earnings report the stock price went up 1.225%.
Which hedge fund is a major shareholder of Jade Biosciences?
Currently, no hedge funds are holding shares in JBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jade Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$29.70 (91.74% Upside)
$29.70 (91.74% Upside)
Hedge Fund Trend
Increased
By 4.8M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.2%
Last 30 Days ▲ 89.6%
Last 30 Days ▲ 89.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
10.45%
12-Months-Change
Fundamentals
Return on Equity
-50.23%
Trailing 12-Months
Asset Growth
100.52%
Trailing 12-Months
Company Description
Jade Biosciences
Jade Biosciences, Inc. is a biotechnology company focused on developing best-in-class therapies to address critical unmet needs in autoimmune diseases. Their lead asset, JADE-001, targets the anti-A PRoliferation-Inducing Ligand (APRIL) pathway for the treatment of immunoglobulin A (IgA) nephropathy. JADE-001 is anticipated to enter clinical trials in the second half of 2025, with initial data expected in the first half of 2026. The company's pipeline also includes two preclinical antibody programs, JADE-002 and JADE-003.
JBIO Stock 12 Month Forecast
Average Price Target
$29.70
▲(91.74% Upside)
Technical Analysis
Ownership Overview
13.01% Insiders
13.66% Mutual Funds
58.41% Other Institutional Investors
7.09% Public Companies and
Individual Investors